Dutch Life Science VCs Swanbridge and Health Innovtions investment helps FABPulous to market
Rotterdam, October 10th, 2017 – Dutch medical start-up FABPulous B.V. welcomed a new round of investment on Tuesday led by Dutch Life Science Venture fund Swanbridge Capital that
Read More
FABPulous founder Jan Glatz Nominated for European Inventor 2018
MAASTRICHT, Oct 16, 2017 – The EASME at the European Commission nominated FABPulous BV’s founder Jan Glatz and Ger Biesbrouck of Medavinci Development, Amsterdam on Monday for the
Read More
FABPulous Wins New EU Patents for Unique Integrated Assay Concept
Maastricht, Netherlands, May 3, 2017 – Dutch point of care diagnostics solution company FABPulous BV won new patents across the European Union on Wednesday for the unique Integrated
Read More
Cracking the chest pain problem
FABPulous develops and markets pioneering solutions for better diagnostics in primary care and emergency medicine More than six out of 10 people referred for observation when complaining of
FABPulous wins €1.6m EU grant for clinical trials of 5 minute heart attack test
The European Union awarded FABPulous BV a €1.6 million Phase 2 grant to fund two clinical trials in the UK and Belgium/Netherlands and automate the manufacture of its
FABPulous BV Announces evolved Executive Management Team
Following successful completion of the €2.2m Series B funding round, FABPulous BV reorganises roles within an enlarged management team to meet the challenges of evolution from R&D start
Press Release – Successful Closure Series B Funding
FABPulous BV closes Series B Funding; Begins commercial activities with rapid 5-minute point-of-care IVD for myocardial infarction based on H-FABP February 4th 2015; Maastricht – Today FABPulous B.V.
FABPulous CEO Interview at Horizon 2020 launch in Brussels
FABPulous was delighted to be notified in December 2014 that it would be awarded an exceptional 100% contribution grant for €1.63m to fund clinical trials for use of